NEW YORK, Feb. 14, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n
Emerging Microbiology Tests and Companies Developing New Technologies and Products <\/p>\n
http:\/\/www.reportlinker.com\/p0771110\/Emerging-Microbiology-Tests-and-Companies-Developing-New-Technologies-and-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic<\/a> <\/p>\n This 650-page report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects for nearly 80 infectious diseases and viruses, including their scientific background, clinical significance and market needs for both current and emerging tests, vaccines, drugs and extensive listings of companies developing or marketing new technologies and products. <\/p>\n Contains 650 pages and 47 tables <\/p>\n Table of Contents <\/p>\n 1. AIDS <\/p>\n a. Background <\/p>\n 0 Structure and Composition <\/p>\n 0 Classification <\/p>\n 0 Origin of AIDS <\/p>\n 0 Animal Lentivirus Systems <\/p>\n 0 Virus Receptos <\/p>\n 0 HIV Infections in Humans <\/p>\n - Pathogenesis & Pathology: Overview of <\/p>\n HIV Infection Course <\/p>\n 0 CD4T Lymphocytes and Memory Cells <\/p>\n 0 Monocytes and Macrophages <\/p>\n 0 Lymphoid Organs <\/p>\n 0 Neural Cells <\/p>\n 0 Viral Coinfections <\/p>\n - Clinical Findings <\/p>\n 0 Plasma Viral Load <\/p>\n 0 Pediatric AIDS <\/p>\n - Neurologic Disease <\/p>\n - Opportunistic Infections <\/p>\n - Cancer <\/p>\n 0 Immunity <\/p>\n - Virus Isolation <\/p>\n - Serology <\/p>\n - Detection of Viral Nucleic <\/p>\n Acid and Antigens <\/p>\n 0 Infectivity <\/p>\n 0 Epidemiology <\/p>\n - Worldwide Spread of AIDS <\/p>\n - United States <\/p>\n - Routes of Transmission <\/p>\n b. Diagnostic Tests0 Laboratory Diagnosis- Enzyme Immunoassay Interpretation- Specific, Sensitivity, and PredictiveValue of Enzyme Immunoassays0 Competition Assays0 Western Blot Technique0 Immuno-Fluorescence Assay (IFA)0 Radioimmunoprecipitation0 HIV-1\/HIV-2 Combination Testing0 Methods of HIV-Antigen Detection0 Antigen Assays and Blood Screening0 Urine Tests0 Immunopathogenic Mechanism of HIV Infection0 DNA Probes- Overview- Quantitative Polymerase Chain Reaction- In Situ PCR- Needed Improvements0 Viral Load\/Drug Resistance Testing0 Genotype and Phenotype Testing0 Blood Banking Considerationc. Vaccines and Drugs- Antiviral Drugs- Vaccines Against HIV0 Transmission of HIV in Blood Products0 HIV Transmission in Transplant andArtificial Insemination Recipients2. Adenovirusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugsd. Adeno-Associated Viruses(AAV)3. Aeromonasa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs4. Anthrax\/Bacillus Anthracisa. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 5. Arboviruses <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 6. Babesiosis <\/p>\n a. Background <\/p>\n 7. Bacillary Epithelioid Angiomatosis (BEA) <\/p>\n And Other Bartonella (Rochalimaea) <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 8. Blastocystis Hominis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 9. Brucella <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 10. Campylobacter <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n 0 Identification from Culture <\/p>\n c. Vaccines and Drugs <\/p>\n 11. Candida <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 12. Chagas Disease <\/p>\n a. Background <\/p>\n 13. Chancroid <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 14. Chlamydia <\/p>\n a. Background <\/p>\n 0 Chlamydia Psittaci <\/p>\n 0 Chlamydia Pneumoniae0 Chlamydia Trachomatisb. Diagnostic Testsc. Vaccines and Drugs15. Clostridium Difficilea. Background0 Pediatric Infections0 Epidemiologyb. Diagnostic Tests0 Counterimmunoelectrophoresis0 Fluorescent-Antibody Assays0 Poloymerase Chain Reactionsc. Drugs and Vaccines16. Coronavirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs17. Coxsackievirusesa. Background0 Herpangina0 Hand-foot-and-mouth syndrome0 Hepidemic Conjuctivitis0 Pharingitis0 Epidemic Pleurodynia0 Myodarditis,Pericarditis0 Overwhelming Infection of the Newborn0 Acute Aseptic Meningitis0 Undifferentiated Febrile Illness0 Fever with upper respiratory infection0 Encephalitis0 Asymptomatic Infectionb. Diagnostic Testsc. Vaccines and Drugs18. Creutzfeldt-Jakob's Diseasea. Background0 Blood Transmissionb. Diagnostic Tests0 Major Commercial and Academic Players- Bayer <\/p>\n - Disease Sciences\/Bio Tec Global <\/p>\n - Imperial College of Medicine <\/p>\n - Ortho-Clinical Diagnostics <\/p>\n - Pall <\/p>\n - ProMetic Life Sciences <\/p>\n - Proteome Sciences\/Idexx <\/p>\n - Q-One Biotech <\/p>\n - Serono <\/p>\n - U.S. Agricultural Research Service <\/p>\n c. Vaccines <\/p>\n 19. Cryptosporidium Parvum <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n 0 Histologic <\/p>\n 0 Laboratory Parasitology <\/p>\n 0 Serodiagnosis <\/p>\n c. Vaccines and Drugs <\/p>\n 20. Cyclospora Cayetanensis <\/p>\n a. Background <\/p>\n 0 Asymptomatic Infection <\/p>\n 0 Diarrhea in Immunocompetent Persons <\/p>\n 0 Diarrhea in Immunocompromisedersons <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 21. Cytomegalovirus <\/p>\n a. Background <\/p>\n 0 Chorioretinitis <\/p>\n 0 Gastrointestinal <\/p>\n 0 Central Nervous System Disease <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 22. Ebola Virus <\/p>\n a. Background <\/p>\n 0 Epidemiology <\/p>\n 0 Hemorrhagic Fever <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 23. E. Coli <\/p>\n a. Background <\/p>\n 0 Role of Escherichia Coli inCausing Diarrhea0 EPEC0 ETEC0 EIEC0 EHECb. Diagnostic Testsc. Vaccines and Drugs24. EchoVirusa. Background0 Acute Aseptic Miningitisis0 Encephalitis0 Exanthems0 Respiratory Disease0 Myope;ricarditis0 Neonatal Infectionsb. Diagnostic Testsc. Vaccines and Drugs25. Encephalitisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs26. Enterovirusesa. Backgroundb. Diagnostic Tests0 Viral Isolation and Identification0 Antibody Testsc. Vaccines and Drugs27. Epstein-Barr Virusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs28. Giardia Lambliaa. Background0 Life Cycle and Morphology0 Morphology of Trophozoites0 Clinical Diseaseb. Diagnostic Testsc. Vaccines and Drugs <\/p>\n 29. Gonorrhea <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 30. Granuloma Inguinale <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 31. Hantavirus <\/p>\n a. Background <\/p>\n 0 Identification of the Agent <\/p>\n 0 Transmission <\/p>\n 0 Other Rodent Hantaviruses <\/p>\n 0 Distribution <\/p>\n 0 Hantavirus Diseases <\/p>\n 0 Epidemiology <\/p>\n 0 Addendum in Proof-Northeastern Connection <\/p>\n 0 Previously Unknown Pathogens <\/p>\n 0 Cases Nationwide <\/p>\n b. Diagnostic Tests <\/p>\n 0 An Immunohistochemistry Approach <\/p>\n 0 Hantavirus Rapid Diagnostic Test <\/p>\n 0 ELISA Diagnosis of Hantavirus Pulmonary <\/p>\n Syndrome <\/p>\n 0 IgG ELISA <\/p>\n 0 IgM Capture ELISA <\/p>\n c. Vaccines and Drugs <\/p>\n 32. Helicobacter Pylori <\/p>\n a. Background <\/p>\n 0 Pathogenesis <\/p>\n 0 Role in Peptic Ulcer Disease <\/p>\n 0 Role in Gastric Cancer <\/p>\n 0 Nonulcer Dyspepsia <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Specific Therapeutic Regimens <\/p>\n 0 Who Should Be Treated? <\/p>\n 0 Participants in Controlled Clinical Trials <\/p>\n 0 Patients with Refractory Peptic Ulcer0 Patients with Refractory NUD0 Patients in High-Risk Groups for GastricCancer33. Hepatitisa. Backgroundb. Hepatitis Ac. Hepatitis Bd. Hepatitis C0 Classification0 Transmission of Infection0 Occupational Hazards0 Acute Hepatitis0 Diagnosis of Acute Infection0 Chronic Hepatitis0 HCV and Other Chronic Liver Diseases0 Alcoholic Liver Disease0 Hepatitis B Coinfection0 Cirrhosis and Hepatocellular Carcinoma0 Diagnostic Tests0 Possible Indications for HCV RNA Testing0 Conclusions and Future Directione. Hepatitis D0 Historical Perspective0 Epidemiology0 HBV-HDV \"Coinfection\" vs. \"Superinfection\"0 Methods of Detecting HDV0 Preventionf. Hepatitis E0 Background0 Prevalence of the Disease0 Diagnostic Tests0 Epidemiologic Serosurveys0 Serologic Cross-Reactivityg. Hepatitis G0 Vaccines and Drugs34. Herpes Simplex Virusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs <\/p>\n 35. Human Herpes Virus-6 (HHV-6) <\/p>\n a. Background <\/p>\n 0 HIV-6 Infections <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 36. Influenza Viruses <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 37. Legionella <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 38. Lyme Disease <\/p>\n a. Background <\/p>\n 0 Clinical Description <\/p>\n 0 Clinical Case Definition <\/p>\n 0 Laboratory Criteria for Diagnosis <\/p>\n 0 Case Classification <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 39. Lymphogranuloma Venereum (LGV) <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 40. Malaria <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n 0 Potential Diagnositic Problems with Positive <\/p>\n Patients from Non-endemic Areas <\/p>\n - Patient <\/p>\n - Laboratory <\/p>\n - Physician <\/p>\n c. Vaccines and Drugs <\/p>\n 41. Measles (Rubeola) <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 42. Meningitisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Development of Polysaccharide Vaccines0 Quadrivalent Vaccine Development0 Meningococcal A.C.Y. & W-135 Vaccines0 Efficacy of Group C Vaccine0 Efficacy of Group A Vaccine0 Combinations of Group A and C Vaccines0 Group B Efficacy Trials0 Future Direction43. Microsporidiuma. Background0 Prevalence and Geographic Distribution0 Sources of Human Infection and Transmissionb. Diagnostic Tests0 Light Microscopic Examination of StoolSpecimens By Chromotrope Staining0 Stool Concentration Methods0 Chemofluorescent Agents0 Giemsa Staining of Stool Specimens0 Cytologic Diagnosis0 Histologic Examination0 Electron Microscopy0 Examination of Bodily Fluids0 Examination of Tissue Sections0 Immunofluorescence Detection Procedures0 Serology0 Cell Culture0 Approach to Diagnosis0 Evaluation of Patients with PresumptiveIntestinal Microsporidiosis0 Evaluation of Patients with PresumptiveOcular Microsporidiosisc. Vaccines and Drugs44. Mononucleosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs <\/p>\n 45. Mumps <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Efficacy of Vaccination <\/p>\n 0 Future Issues <\/p>\n 46. Mycoplasma <\/p>\n a. Background <\/p>\n 0 Ureaplasma Urealyticum & Mycoplasma Hominis <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 47. Papillomaviruses <\/p>\n a. Background <\/p>\n 0 HPV in Cancer <\/p>\n 0 Cervical Neoplasm <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Prevention <\/p>\n 48. Parvovirus B19 <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 49. Pneumonia <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 50. Polyomaviruses <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 51. Pseudomonas Aeruginosa <\/p>\n a. Background <\/p>\n 0 Virulence Factors <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 52. Rabies <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 53. Respiratory Syncytial Virus (RSV)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs54. RhinoVirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs55. RotaVirus (REOVIRUS)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs56. Rubella(MEASLES)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Developing Countries0 Elimination and Eradication of Measles0 New Developments57. Salmonellosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs58. Septicemiaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs59. Shigellosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs60. Staphylococcus Aureusa. Background0 The Genus Taphylococcusb. Diagnostic Testsc. Vaccines and Drugs0 Prevention61. Streptococcia. Backgroundb. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Group A Streptococci <\/p>\n 0 Group B Streptococci <\/p>\n 62. Syphilis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n 0 Biopsy <\/p>\n 0 Rabbit Infectivity Testing <\/p>\n 0 Other Diagnostic Modalities <\/p>\n c. Vaccines and Drugs <\/p>\n 0 Syphilis and HIV Infection <\/p>\n 0 Syphilis As a Cofactor for HIV Transmission <\/p>\n 0 Basic Science Issues <\/p>\n 63. Toxoplasmosis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 64. Trichomonas Vaginalis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 65. Tuberculosis <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n 0 Microscopic Characteristics <\/p>\n 0 Cultural Characteristics <\/p>\n 0 Detection of Antibodies <\/p>\n 0 Skin Tests <\/p>\n 0 MDRTB <\/p>\n c. Vaccines and Drugs <\/p>\n 66. Vibrio <\/p>\n a. Background <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 67. West Nile Virus <\/p>\n a. Background <\/p>\n - Clinical Syndromes <\/p>\n b. Diagnostic Tests <\/p>\n c. Vaccines and Drugs <\/p>\n 68. Yersinaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs <\/p>\n List of Tables <\/p>\n Major Companies Developing or Marketing AIDS TestsMajor Companies Developing or Marketing AdenovirusTestsMajor Companies Developing or Marketing BartonellaTestsMajor Companies Developing or MarketingCampylobacter TestsMajor Companies Developing or Marketing CandidaTestsMajor Companies Developing or Marketing ChlamydiaTestsMajor Companies Developing or Marketing ClostridiumTestsMajor Companies Developing or Marketing CoronavirusTestsMajor Companies Developing or Marketing CryptosporidiumTestsMajor Companies Developing or Marketing CMV TestsMajor Companies Developing or Marketing EchovirusTestsMajor Companies Developing or Marketing EnterovirusTestsMajor Companies Developing or Marketing EBV Tests <\/p>\n Major Companies Developing or Marketing Giardia <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Gonorrhea <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Hantavirus <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Helicobacter <\/p>\n Pylori Tests <\/p>\n Major Companies Developing or Marketing Hepatitis <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Herpes <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Influenza <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Legionella <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Lyme Disease <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Lymphogranuloma <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Malaria <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Measles <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Meningitis <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing MicrosporidiumTestsMajor Companies Developing or MarketingMononucleosis TestsMajor Companies Developing or Marketing Mumps TestsMajor Companies Developing or Marketing MycoplasmaTestsMajor Companies Developing or Marketing PapillomaVirus TestsMajor Companies Developing or Marketing ParvovirusTestsMajor Companies Developing or Marketing PneumoniaTestsMajor Companies Developing or Marketing RSV TestsMajor Companies Developing or Marketing RotavirusTestsMajor Companies Developing or Marketing RubellaTestsMajor Companies Developing or Marketing SalmonellaTestsMajor Companies Developing or Marketing SepticemiaTestsMajor Companies Developing or Marketing ShigellaTestsMajor Companies Developing or Marketing StaphylococciTests <\/p>\n Major Companies Developing or Marketing <\/p>\n Streptococci Tests <\/p>\n Major Companies Developing or Marketing Syphilis <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Toxoplasmosis <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Trichomonas <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Tuberculosis <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing West Nile <\/p>\n Tests <\/p>\n Major Companies Developing or Marketing Yersinia Tests <\/p>\n To order this report:In Vitro Diagnostic Industry: Emerging Microbiology Tests and Companies Developing New Technologies and Products <\/p>\n More <\/p>\n Market Research Report <\/p>\n Check our <\/p>\n Industry Analysis and Insights <\/p>\n <\/p>\n Nicolas Bombourg Read this article: NEW YORK, Feb. 14, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Emerging Microbiology Tests and Companies Developing New Technologies and Products http:\/\/www.reportlinker.com\/p0771110\/Emerging-Microbiology-Tests-and-Companies-Developing-New-Technologies-and-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic<\/a> This 650-page report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects for nearly 80 infectious diseases and viruses, including their scientific background, clinical significance and market needs for both current and emerging tests, vaccines, drugs and extensive listings of companies developing or marketing new technologies and products. Contains 650 pages and 47 tables Table of Contents 1 Continue reading
Reportlinker
Email: nbo@reportlinker.com<\/a>
US: (805)652-2626
Intl: +1 805-652-2626 <\/p>\n<\/p>\n
\nEmerging Microbiology Tests and Companies Developing New Technologies and Products<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"